From claims to clarity with MarketScan longitudinal data
As the healthcare research landscape evolves, researchers face growing challenges related to longitudinal data quality, patient continuity, and dataset limitations that can skew feasibility, bias, and overall real‑world evidence outcomes. Why does it matter so profoundly to track people as they change health plans? This can impact eligibility windows, sample retention, and analytic rigor. As payer churn increases and gaps in claims-only datasets become more evident, the need for a trusted, comprehensive longitudinal foundation has never been greater.
This webinar cuts through the noise and focus on practical implications, real-world scenarios, and the reasons MarketScan continues to be the backbone of reliable healthcare research.
Viewers will:
-
Gain a deeper understanding of how longitudinal completeness and continuous eligibility windows directly shape study feasibility, bias, and power
-
Explore the real cost and burden implications of mis-specified longitudinality, including how errors in tracking patient journeys can distort economic models and HEOR findings
-
See how MarketScan’s combined data, tools, and services deliver differentiated value
This is an essential session for anyone responsible for designing, executing, or interpreting real-world evidence. Watch to strengthen your understanding of why MarketScan remains the superior foundation for longitudinal healthcare research.
Speakers
Liisa Palmer, PhD
Portfolio Leader, Real World Data Research & Analytics, MarketScan
Rachel Connolly
Sr. Director of Alliance Partnerships, MarketScan
Luke Boulanger
Director, Technology Product Management, MarketScan
Insights from MarketScan
More on real-world data
MarketScan Spotlight, Winter 2026
MarketScan covers AI's expanding role with real-world data, discusses new episodes of its podcast series, and highlights the important role of the MarketScan Research & ...
Unlock value with MarketScan’s advanced data linking
Experts from MarketScan and Biodesix explored how advanced data linking drives deeper understanding, better decision‑making, and measurable organizational value.
Quality over quantity: What the FDA’s single trial shift means for real-world data
Read more about the FDA's recent pivot toward accepting one adequate and well controlled trial instead of two, and what it means for real-world data.